Pediatrix Medical Group (MD) AI Stock Analysis

• Market Cap: $2.07B
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.48
• Revenue Growth: -4.21%
• EPS Growth: N/A
• Country: US
• Employees: 4,120
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.67
• Shares Outstanding: 85,877,390
• 10 Day Avg. Volume: 1,202,104
• 30 Day Avg. Volume: 1,068,311
• PEG Ratio: -0.17
• Price to Book (P/B): 1.43
• Price to Sales (P/S): 0.54
• P/FCF Ratio: 5.92
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.84
• Enterprise Value/Gross Profit: 3.25
• Enterprise Value/Ebitda: 6.25
• 1Y Price Target: $21.33
• Price Target Upside: -11.46% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 2.08
• Revenue Forecast (FY): $1.90B

• Rating: 76 Outperform
• Price Target: $25.00 ▲(3.78% Upside)

Pediatrix Medical Group's stock is rated positively due to strong technical indicators and solid financial performance, particularly in cash flow generation and leverage improvement. The earnings call reinforced this with exceeded EBITDA expectations and strategic initiatives. However, challenges like declining revenue growth and increased G&A expenses slightly temper the overall outlook.

Positive Factors

Cash Flow Generation

Strong cash flow growth indicates robust operational efficiency, providing the company with flexibility for investments and debt reduction.

Innovative Technology

The implementation of BabySteps showcases Pediatrix's commitment to innovation, potentially improving patient outcomes and strengthening market position.

Same-Unit Growth

Consistent same-unit growth reflects strong demand for services, indicating a stable revenue base and effective pricing strategies.

Negative Factors

Revenue Decline

The revenue decline from restructuring suggests potential challenges in maintaining sales levels, impacting long-term growth prospects.

Increased G&A Expenses

Rising G&A expenses can pressure margins, potentially reducing profitability and limiting resources for strategic initiatives.

Declining Profit Margins

Decreasing profit margins indicate cost pressures or pricing challenges, which could hinder long-term financial performance.

Pediatrix Medical Group Business Overview & Revenue Model

Company Description

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

How the Company Makes Money

Pediatrix Medical Group generates revenue primarily through its healthcare services, billing insurance companies, government programs, and patients for the medical services provided. Key revenue streams include professional fees for consultations, inpatient and outpatient care, and specialized services in their pediatric subspecialties. The company also benefits from strategic partnerships with hospitals and healthcare systems, which can provide a steady stream of patients and referrals. Additionally, Pediatrix may receive reimbursements from both private and public payers, which are critical to their financial model, as well as payments for bundled services that encompass a range of pediatric health issues.

Pediatrix Medical Group Financial Statement Overview

Summary

Pediatrix Medical Group shows a solid financial position with strong cash flow generation and improved leverage. However, challenges include declining revenue growth and profit margins, which need addressing to enhance profitability.

Income Statement

Pediatrix Medical Group shows a mixed performance in its income statement. The TTM data indicates a gross profit margin of 18.16% and a net profit margin of 8.44%, which are reasonable but have declined from previous periods. The revenue growth rate is negative, indicating a contraction in sales. However, the company has improved its EBIT and EBITDA margins compared to the previous year, suggesting better operational efficiency.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio has improved to 0.72 in the TTM, indicating a reduction in leverage. Return on equity is strong at 19.79%, showing effective use of equity to generate profits. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Cash flow analysis reveals a positive trend with a 20.44% growth in free cash flow in the TTM. The operating cash flow to net income ratio is 0.75, indicating healthy cash generation relative to net income. The free cash flow to net income ratio is high at 0.94, suggesting strong cash flow coverage of earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.92B	2.01B	1.99B	1.97B	1.91B	1.73B
Gross Profit	496.25M	454.34M	421.56M	467.03M	513.24M	449.32M
EBITDA	258.29M	-28.37M	29.89M	156.70M	236.10M	146.07M
Net Income	162.19M	-99.07M	-60.41M	66.33M	130.96M	-796.49M
Balance Sheet
Total Assets	2.20B	2.15B	2.22B	2.35B	2.72B	3.35B
Cash, Cash Equivalents and Short-Term Investments	463.10M	348.51M	177.74M	103.06M	487.11M	1.23B
Total Debt	642.27M	662.31M	701.65M	717.08M	1.07B	1.80B
Total Liabilities	1.31B	1.39B	1.37B	1.46B	1.83B	2.60B
Stockholders Equity	890.67M	764.94M	849.06M	891.63M	896.49M	747.49M
Cash Flow
Free Cash Flow	273.39M	184.55M	104.00M	137.23M	44.49M	175.83M
Operating Cash Flow	290.00M	206.57M	137.32M	166.94M	76.74M	204.62M
Investing Cash Flow	-9.95M	-35.41M	-48.18M	-56.95M	-53.07M	815.51M
Financing Cash Flow	-43.82M	-14.48M	-25.71M	-487.55M	-760.12M	-4.16M

Pediatrix Medical Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MD, the sentiment is Positive. The current price of 24.09 is above the 20-day moving average (MA) of 22.52, above the 50-day MA of 19.10, and above the 200-day MA of 15.50, indicating a bullish trend. The MACD of 1.53 indicates Negative momentum. The RSI at 75.20 is Negative, neither overbought nor oversold. The STOCH value of 78.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MD.

Pediatrix Medical Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MD	76 Outperform	$2.07B	12.72	19.98%	―	-4.21%	―
NHC	72 Outperform	$2.11B	21.03	9.94%	1.97%	23.74%	-18.99%
HCSG	72 Outperform	$1.32B	34.75	8.07%	―	6.26%	-19.33%
SEM	69 Neutral	$1.66B	15.35	5.57%	1.61%	-22.96%	-59.35%
ASTH	56 Neutral	$1.16B	121.26	1.29%	―	68.17%	-85.42%
AVAH	54 Neutral	$1.94B	25.75	―	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pediatrix Medical Group Corporate Events

Pediatrix Medical Group Announces Share Repurchase Program

On August 18, 2025, Pediatrix Medical Group announced a $250 million share repurchase program authorized by its Board of Directors. The program, which aims to utilize the company’s strong cash flow and low debt levels, will be executed over a three-year term through various transaction methods. This strategic move is intended to provide long-term returns to shareholders and strengthen the company’s future business prospects.

The most recent analyst rating on (MD) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Pediatrix Medical Group stock, see the MD Stock Forecast page.